AlphaQuest LLC Purchases 4,237 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

AlphaQuest LLC raised its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 1,891.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,461 shares of the biotechnology company’s stock after buying an additional 4,237 shares during the quarter. AlphaQuest LLC’s holdings in AnaptysBio were worth $59,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Victory Capital Management Inc. grew its holdings in shares of AnaptysBio by 41.0% during the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company’s stock valued at $4,428,000 after purchasing an additional 97,200 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of AnaptysBio by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company’s stock valued at $2,199,000 after purchasing an additional 5,733 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of AnaptysBio during the 4th quarter valued at approximately $311,000. Rhumbline Advisers grew its holdings in shares of AnaptysBio by 3.8% during the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 1,111 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of AnaptysBio by 1.6% during the 4th quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock valued at $3,563,000 after purchasing an additional 4,242 shares during the last quarter.

Insider Activity at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 65,184 shares of the company’s stock in a transaction on Monday, December 30th. The shares were purchased at an average cost of $12.92 per share, with a total value of $842,177.28. Following the completion of the purchase, the director now owns 7,860,180 shares in the company, valued at $101,553,525.60. This represents a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 33.70% of the stock is currently owned by company insiders.

AnaptysBio Price Performance

Shares of ANAB stock opened at $17.57 on Friday. The business’s 50 day simple moving average is $16.74 and its 200 day simple moving average is $22.81. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $41.31. The stock has a market capitalization of $538.82 million, a PE ratio of -2.89 and a beta of 0.02.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $43.11 million for the quarter, compared to analysts’ expectations of $10.17 million. As a group, research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ANAB. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial decreased their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Wolfe Research began coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a research note on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus target price of $35.11.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.